-logo-1200x675.png?v=20220915161652&w=240&h=240&zc=2){kind=logo}
Equities Analysts Set Expectations for ACRS Q1 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Aclaris Therapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the biotechnology company will earn ($0.13) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” […]
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Aclaris Therapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the biotechnology company will earn ($0.13) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” […]
